Glioblastoma Multiforme

Every year, almost a quarter of a million people worldwide are diagnosed with Glioblastoma multiforme (GBM). It is the most lethal yet unfortunately most common brain tumour with no cure to date. The standard-of-care currently available for GBM patients is surgical removal of the affected brain tissue, followed by a combination of radio- and chemotherapy. This non-curative treatment regimen is both physically and financially demanding for the patient and costly for the global healthcare system, giving the patients an average of around 15 months survival benefit.